In the comparison between CADM and CDM, we found that patients with CADM showed significantly higher anti-MDA5 antibody levels and significantly higher ILD, RP-ILD, mortality, and 1-year mortality rates than those with CDM, which were similar to the findings of a previous study (30). The gene discussed is IFIH1; the disease is clinically amyopathic dermatomyositis.